The cobas h 232: for on-the-spot cardiac decisions
Are you interested in reducing referrals for heart failure in primary care? By providing rapid, accurate results near the patient, POC testing speeds up diagnosis and treatment, improving clinical outcomes and ensuring patients are managed efficiently and more cost-effectively
By implementing a simple and fast blood test in primary care, health professionals can rule out heart failure without the need for an echocardiogram (ECHO). The test is NT-proBNP, a natriuretic peptide. When the ventricle is stretched in heart failure it secretes a natriuretic protein which is broken down in the blood to NT-proBNP.
The cobas h232 can detect the concentration of NT-proBNP in the blood with a simple 12-minute test. If NT-proBNP is below a certain level heart failure can be ruled out. If NT-proBNP is above a certain level the patient can be receive an ECHO to confirm if heart failure is present. National Institute for Health and Clinical Excellence (NICE) guidelines recommend that, where available, NT-proBNP be tested in the diagnosis of heart failure. It is estimated that approximately 60% of patients who are referred from primary care to have an ECHO on suspicion of heart failure do not actually have heart failure. Testing for NT-proBNP in primary care can prevent these referrals, which will have many benefits, including:
Save undue stress on the patient.
Speed up the diagnostic process enabling a faster time to the correct treatment.
Save the NHS money by reducing costly referrals.
NT-proBNP testing has already been successfully implemented in a number of PCOs across the UK and these benefits are now being realised.
For further information on how to achieve the benefits of this test and other tests on the cobas h232 (D-dimer, TroponinT), and for advice on how to implement a service in primary care, please contact Roche Diagnostics on: 01444 256000 (ask for point of care) or email: email@example.com